Pfizer Inc. today announced positive results from Cohort 3, a separate randomized cohort of the pivotal BREAKWATER trial, ...
Over 70 percent of patients in the first-line subgroup responded to amivantamab plus chemotherapy with most responses lasting beyond 16 monthsNotable ...
These are tech expert Marc Salzman's top CES picks for USA TODAY after his hands-on with future gadgets and gear in Las Vegas ...
Every January, National Blood Donor Month honors the generous donors who help maintain our blood supply, appreciates the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback